← 홈

CGT · 방광·요로상피

4개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4개
CGTSHOTFDACuratedFDABiologicFerring PharmaceuticalsHuman interferon alfa-2bApproved

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) · IFNα2b (adenoviral)

#IFN2badenoviral#CGT#Approved#FDA승인#바이오정보모아추천+5
효능 ORR 55%임상시험 10상태 APPROVED
CGTBiologicstaleSPP Pharmaclon Ltd.Phase 2

Recombinant Interferon Alfa (Recombinant Interferon Alfa)

Colorectal Cancer; Kidney Cancer · Bladder Cancer

#BladderCancer#CGT#Phase2#인기#세포유전치료+5
효능 ORR 32.4%임상시험 59상태 ACTIVE
CGTBiologicstaleThe Affiliated Hospital of Xuzh…Phase 1

Recombinant oncolytic adenovirus injection solution of VT-101 (Recombinant oncolytic adenovirus injection solution of VT-101)

Non-muscle Invasive Bladder Cancer · Non-muscle Invasive Bladder Cancer

#Non-muscleInvasiveBladderCancer#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleCG Oncology, Inc.Phase 2

oncolytic adenovirus expressing GMCSF (oncolytic adenovirus expressing GMCSF)

Bladder Cancer; High Grade · Bladder Cancer

#BladderCancer#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 5%임상시험 1상태 DISCONTINUED